Mariner LLC Buys 30,704 Shares of AbbVie Inc. $ABBV

Mariner LLC grew its stake in shares of AbbVie Inc. (NYSE:ABBV) by 2.3% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,370,393 shares of the company’s stock after buying an additional 30,704 shares during the quarter. Mariner LLC owned approximately 0.08% of AbbVie worth $313,145,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Chelsea Counsel Co. bought a new stake in shares of AbbVie in the third quarter worth $26,000. Litman Gregory Wealth Management LLC acquired a new stake in AbbVie in the fourth quarter valued at $28,000. Westend Capital Management LLC bought a new position in AbbVie during the 4th quarter worth $29,000. IFC & Insurance Marketing Inc. acquired a new position in AbbVie during the 4th quarter worth about $31,000. Finally, Texas Capital Bancshares Inc TX acquired a new position in AbbVie during the 3rd quarter worth about $31,000. Institutional investors own 70.23% of the company’s stock.

AbbVie Price Performance

Shares of NYSE:ABBV opened at $227.54 on Monday. AbbVie Inc. has a 1 year low of $181.73 and a 1 year high of $244.81. The business’s 50-day moving average is $211.05 and its 200-day moving average is $219.00. The company has a market capitalization of $402.02 billion, a price-to-earnings ratio of 112.09, a P/E/G ratio of 0.70 and a beta of 0.32.

AbbVie (NYSE:ABBV) last released its earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, topping the consensus estimate of $2.59 by $0.06. The business had revenue of $15 billion during the quarter, compared to analysts’ expectations of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The firm’s revenue was up 12.4% on a year-over-year basis. During the same quarter last year, the firm posted $2.46 earnings per share. Analysts anticipate that AbbVie Inc. will post 14.3 EPS for the current year.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie said nine-year CLL14 data showed venetoclax plus obinutuzumab delivered durable progression-free survival in previously untreated chronic lymphocytic leukemia, strengthening the case for the drug’s long-term commercial value. AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
• Positive Sentiment: Investors are also focused on AbbVie’s broader pipeline and franchise strength, with commentary pointing to Skyrizi and Rinvoq continuing to drive revenue growth, which supports the company’s outlook beyond legacy Humira. Will Skyrizi & Rinvoq Continue to Drive AbbVie’s Topline Through 2026?
• Neutral Sentiment: Several market commentaries described AbbVie as a defensive, high-quality compounder, but noted the shares may not be cheap at current levels, which suggests valuation may temper upside even with strong fundamentals. AbbVie: A Defensive Compounder Worth Holding, But Not A Bargain Buy
• Negative Sentiment: One article highlighted regulatory risk around AbbVie’s fast-acting neurotoxin TrenibotE after an FDA complete response letter, which could delay a potential growth driver if development setbacks persist. FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research note on Monday, June 8th. Evercore set a $235.00 target price on AbbVie in a report on Friday, May 15th. DZ Bank raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Thursday, April 30th. Wall Street Zen lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating in a report on Sunday, June 7th. Finally, Morgan Stanley boosted their price target on shares of AbbVie from $270.00 to $278.00 and gave the stock an “overweight” rating in a research report on Thursday, April 30th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $253.43.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.